The US Food and Drug Administration has approved the first respiratory syncytial virus (RSV) vaccine for use in the United States, the Public Health Agency announced recently.
The drug, called Arixvi, is approved for use by people 60 or older to prevent RSV.
What is “respiratory syncytial virus”?
• A virus that causes infections in the lungs and respiratory tract.
• It is so common that most children have it before they are two years old.
• The virus can also infect adults.
• For healthy older adults and children, the symptoms of the virus are mild, usually similar to those of a cold.
• Self-care measures are usually all that is needed to relieve the feeling of illness.
seriousness of the virus
But the director of the US Food and Drug Administration’s Center for Biology, Peter Marks, said: “Older adults, especially those with special health conditions such as heart or lung disease or a weakened immune system, are at increased risk of serious illness caused by RSV.”
“The approval of the first RSV vaccine is an important public health achievement for preventing a potentially life-threatening disease and reflects the FDA’s continued commitment to facilitating the development of safe and effective vaccines for use in the United States.”
Vaccine benefits
The US Food and Drug Administration conducted an ongoing, randomized, placebo-controlled clinical study to ensure the safety and effectiveness of Arixvi. For a single dose for people 60 years of age or older, according to Fox News.
Of the 25,000 study participants, half received the vaccine and half received a placebo.
The US Food and Drug Administration said, “The vaccine significantly reduced the risk of developing RSV-related illnesses. with a rate ranging between 82.6 and 94.1 percent.
2023-05-07 12:22:50
#time.. #Approval #vaccine #virus #affects #people
